The purpose of the study is to determine the effect of metformin on dapagliflozin exposure and the effect of dapagliflozin on metformin exposure in healthy volunteers. Additionally, the safety and tolerability of dapagliflozin will be assessed in the presence and absence of metformin in healthy volunteers
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Masking
NONE
Enrollment
18
Tablets, Oral, 20 mg, once daily single dose
Tablets, Oral, 1000 mg, once daily, single dose
Tablets, Oral, once daily, single dose Dapagliflozin: 20 mg Metformin: 1000 mg
Bristol-Myers Squibb Clinical Pharmacology Unit
Hamilton, New Jersey, United States
To determine the effect of metformin on the exposure of dapagliflozin and the effect of dapagliflozin on the exposure of metformin in healthy subjects after a single dose of each treatment
Time frame: measures taken daily throughout the study
To assess the safety and tolerability of dapagliflozin when administered alone or with metformin after a single dose of each treatment
Time frame: measures will be taken at the beginning and end of the study, as well as 1 time every 3 days (Day -1 of each study period)
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.